Among the many challenges that face manufacturers of human cell-based therapies and medical devices, a few key issues stand out—the ability to scale and the need to reduce risk.
The National Disease Research Interchange (NDRI) has worked for over 40 years to build the infrastructure needed to provide scalable solutions for the acquisition of high-quality human tissue that meet the regulatory demands of cell-based therapies, medical devices, 3D printed human tissue and regenerative medicines. We partner with clients from early phase development through commercial scale production.
Leverage NDRI’s experience in human tissue acquisition services for assistance with:
Our experienced teams ethically source human tissue and organs from FDA 21-CFR compliant Organ Procurement Organizations (OPOs) and Tissue Banks located across the US. NDRI will ensure access to high-quality tissue:
We provide the highest level of service to support your commercial manufacturing needs via 24/7 availability of our scientific staff to consult with you from start to finish.
Exposure to risk is of the utmost concern for many organizations we work with. NDRI has implemented standardized procedures and works only with qualified partnerships to diminish your exposure.
Our team includes highly skilled scientists, compliance specialists, project managers, and experts in procurement and logistics management. They are:
About NDRI: A 501c3 non-profit founded in 1980, NDRI is the nation’s leading source of human tissues, cells and organs for scientific research, and a trusted resource of the National Institutes of Health for over thirty years.
For more information and questions on how NDRI can be your partner of choice, contact our Strategic Initiatives department at email@example.com, 800-222-NDRI (6374), ext. 289